The US Department of Food and Drug Administration (FDA) has formally approved the use of the drug ‘Remdesivir’ in the treatment of hospitalized coronavirus patients. According to research by the National Institutes of Health, ‘The patient may recover in 10 days instead of 15 with the use of this anti-viral drug.’ It was being used in the US since May, but it was meant for serious patients or emergency use. Now, the US has approved the use of Remdesivir in treatment for hospitalized patients.
FDA Commissioner issued statement regarding this:
FDA Commissioner Stephen Hahn said in a statement, “The FDA committed in expediting development and availability of Covid-19 treatments during this unprecedented public health emergency. Today’s approval is supported by data from multiple clinical trials. The agency has rigorously assessed and represents an important scientific milestone in the Covid-19 pandemic.”
However, the WHO said a few days ago that there is no evidence that shows any benefit in reducing mortality or reducing the number of hospital days in the WHO’s Solidarity Trial. However, only a few doctors are questioning this study.
USFDA issued statement regarding this:
On the other hand, USFDA said in a statement, “While both the SOLIDARITY trial and the ACTT-1 trial contribute to our understanding of interventions to help treat COVID-19. The two clinical trials had different trial designs and primary goals. The benefit to patients for Veklury demonstrated based on the findings of the ACTT-1 trial. It includes a shorter time to recovery and better odds of clinical improvement. The SOLIDARITY results do not refute these findings of benefit to patients.”
Like and Follow us on :